Most Popular News Stories on OBR Daily
(New York Times) Oct 14, 2019 - A critical chemotherapy medication is in short supply, and physicians say there is no appropriate substitute. A critical drug that serves as the backbone of treatment for most childhood cancers, including leukemias, lymphomas and brain tumors, has become increasingly scarce, and doctors are warning that they may soon be forced to consider rationing doses.
(BMS) Oct 22, 2019 - Study evaluated Opdivo plus low-dose Yervoy given concomitantly with two cycles of chemotherapy vs. chemotherapy alone for the first-line treatment of advanced non-small cell lung cancer. Bristol-Myers Squibb Company today announced that CheckMate -9LA, a pivotal Phase 3 trial evaluating Opdivo (nivolumab) plus low-dose Yervoy (ipilimumab) given concomitantly with two cycles of chemotherapy for the first-line treatment of advanced non-small cell lung cancer (NSCLC), met its primary endpoint of superior overall survival (OS) at a pre-specified interim analysis. The comparator in this study was chemotherapy alone for up to four cycles followed by optional maintenance therapy. The safety profile of Opdivo plus low-dose Yervoy and two cycles of chemotherapy in CheckMate -9LA was reflective of the known safety profiles of the immunotherapy and chemotherapy components in first-line NSCLC.
(NBC News/Associated Press) Nov 6, 2019 - The first attempt in the United States to use a gene editing tool called CRISPR against cancer seems safe in the three patients who have had it so far, but it’s too soon to know if it will improve survival, doctors reported Wednesday. The doctors were able to take immune system cells from the patients’ blood and alter them genetically to help them recognize and fight cancer, with minimal and manageable side effects.
(Reuters) Oct 22, 2019 - Bristol-Myers Squibb Co said on Tuesday an interim analysis of a late-stage trial testing a combination of its immuno-oncology drugs Opdivo and Yervoy met the main goal of extending life of previously untreated lung cancer patients. Shares of the company rose 5% to $56 in premarket trading. The company said its therapies when administered alongside two courses of chemotherapy demonstrated superior overall survival compared to chemotherapy alone in patients with advanced non-small cell lung cancer, the most common form of the disease.
(AstraZeneca) Oct 17, 2019 - AstraZeneca and Daiichi Sankyo Company, Limited (Daiichi Sankyo) today announced that the US Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for [fam-] trastuzumab deruxtecan (DS-8201) and granted Priority Review. The Prescription Drug User Fee Act (PDUFA) date for trastuzumab deruxtecan, a HER2-targeting antibody drug conjugate (ADC) and potential new medicine for the treatment of HER2-positive metastatic breast cancer, is set for the second quarter of 2020.
(Reuters) Oct 16, 2019 - Eli Lilly and Co said on Wednesday its experimental pancreatic cancer treatment in combination with chemotherapy drugs failed to meet the main goal of overall survival in a late-stage study. Lilly shares fell 1.6% to $108 in premarket trading. The trial evaluated Lilly’s pegilodecakin plus Folfox, which is a combination of chemotherapy drugs, compared to Folfox alone in patients with metastatic pancreatic cancer.
(Washington Post) Oct 23, 2019 - After being criticized for years for not taking more aggressive action, the agency proposes manufacturers use a boxed warning to explain the risks. The Food and Drug Administration, under fire from women who say they were harmed by breast implants, proposed on Wednesday that manufacturers spell out warnings about possible complications from the devices, including rare cancers and the need for additional surgeries.
(Washington Post) Nov 4, 2019 - There’s an inexpensive, widely accessible and markedly effective approach to cancer care that’s as close as the tips of our fingers. It’s not a new drug, type of radiation or surgical breakthrough with a slew of unwelcome side effects. It’s also not a cure, but it is surprising for its simplicity. It’s a matter of regularly answering a few questions about symptoms.
(LLS.org) Oct 21, 2019 - A new study commissioned by The Leukemia & Lymphoma Society finds that patients face steep out-of-pocket costs years after initial diagnosis. Survival of older patients with blood cancers continues to improve as more effective, less toxic therapies are introduced. However, these lifesaving treatments often are expensive and many cancer patients face financial burdens caused by ever-increasing healthcare costs.
(Roche) Oct 21, 2019 - First Phase III cancer immunotherapy study to show an improvement in overall survival and progression-free survival for the treatment of the most common form of liver cancer. Data will be submitted to health authorities globally, including the U.S. Food and Drug Administration, the European Medicines Agency and the China National Medical Products Administration.